These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20463930)

  • 1. Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier.
    Mori Y; Nakamura S; Kishimoto S; Kawakami M; Suzuki S; Matsui T; Ishihara M
    Int J Nanomedicine; 2010 Apr; 5():147-55. PubMed ID: 20463930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel experimental and clinical therapeutic uses of low-molecular-weight heparin/protamine microparticles.
    Kishimoto S; Ishihara M; Takikawa M; Mori Y; Hattori H; Fujita M; Nakamura S
    Pharmaceutics; 2012 Jan; 4(1):42-57. PubMed ID: 24300179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved angiogenesis and healing in crush syndrome by fibroblast growth factor-2-containing low-molecular-weight heparin (Fragmin)/protamine nanoparticles.
    Takikawa M; Nakamura S; Ishihara M; Takabayashi Y; Fujita M; Hattori H; Kushibiki T; Ishihara M
    J Surg Res; 2015 Jun; 196(2):247-57. PubMed ID: 25864985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of FGF-2 and low-molecular-weight heparin/protamine nanoparticles on radiation-induced healing-impaired wound repair in rats.
    Kinoda J; Ishihara M; Nakamura S; Fujita M; Fukuda K; Sato Y; Yokoe H
    J Radiat Res; 2018 Jan; 59(1):27-34. PubMed ID: 29121251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of fragmin/protamine microparticles containing fibroblast growth factor-2 (F/P MPs/FGF-2) to induce collateral vessels in a rabbit model of hindlimb ischemia.
    Horio T; Fujita M; Tanaka Y; Ishihara M; Kishimoto S; Nakamura S; Hase K; Maehara T
    J Vasc Surg; 2011 Sep; 54(3):791-8. PubMed ID: 21620612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled release of FGF-2 using fragmin/protamine microparticles and effect on neovascularization.
    Nakamura S; Kanatani Y; Kishimoto S; Nakamura S; Ohno C; Horio T; Masanori F; Hattori H; Tanaka Y; Kiyosawa T; Maehara T; Ishihara M
    J Biomed Mater Res A; 2009 Dec; 91(3):814-23. PubMed ID: 19051304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-assembled nanocomplex of PEGylated protamine and heparin-suramin conjugate for accumulation at the tumor site.
    Park J; Hwang SR; Choi JU; Alam F; Byun Y
    Int J Pharm; 2018 Jan; 535(1-2):38-46. PubMed ID: 29097141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery system for autologous growth factors fabricated with low-molecular-weight heparin and protamine to attenuate ischemic hind-limb loss in a mouse model.
    Nakamura S; Takikawa M; Ishihara M; Nakayama T; Kishimoto S; Isoda S; Ozeki Y; Sato M; Maehara T
    J Artif Organs; 2012 Dec; 15(4):375-85. PubMed ID: 22890790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomedical application of low molecular weight heparin/protamine nano/micro particles as cell- and growth factor-carriers and coating matrix.
    Ishihara M; Kishimoto S; Takikawa M; Hattori H; Nakamura S; Shimizu M
    Int J Mol Sci; 2015 May; 16(5):11785-803. PubMed ID: 26006248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A way to decylamine-stabilized gold nanoparticles of tailored sizes tuning their growth in solution.
    Evangelisti C; Raffa P; Uccello-Barretta G; Vitulli G; Bertinetti L; Martra G
    J Nanosci Nanotechnol; 2011 Mar; 11(3):2226-31. PubMed ID: 21449372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buccal delivery of low molecular weight heparin by cationic polymethacrylate nanoparticles.
    Mouftah S; Abdel-Mottaleb MMA; Lamprecht A
    Int J Pharm; 2016 Dec; 515(1-2):565-574. PubMed ID: 27773855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminodextran containing magnetite nanoparticles for molecular biology applications: preparation and evaluation.
    Mouaziz H; Veyret R; Theretz A; Ginot F; Elaissari A
    J Biomed Nanotechnol; 2009 Apr; 5(2):172-81. PubMed ID: 20055095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folate-conjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM).
    Zu Y; Zhang Y; Zhao X; Zhang Q; Liu Y; Jiang R
    Int J Nanomedicine; 2009; 4():321-33. PubMed ID: 20054435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion and characterization of human bone marrow-derived mesenchymal stem cells cultured on fragmin/protamine microparticle-coated matrix with fibroblast growth factor-2 in low serum medium.
    Kishimoto S; Hattori H; Nakamura S; Amano Y; Kanatani Y; Tanaka Y; Mori Y; Harada Y; Tagawa M; Ishihara M
    Tissue Eng Part C Methods; 2009 Sep; 15(3):523-7. PubMed ID: 19191666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
    Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlling the growth of "ionic" nanoparticle supracrystals.
    Kalsin AM; Grzybowski BA
    Nano Lett; 2007 Apr; 7(4):1018-21. PubMed ID: 17375966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicochemical characterization of protamine-phosphorothioate nanoparticles.
    Lochmann D; Vogel V; Weyermann J; Dinauer N; von Briesen H; Kreuter J; Schubert D; Zimmer A
    J Microencapsul; 2004 Sep; 21(6):625-41. PubMed ID: 15762320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and characterization of honokiol nanoparticles.
    Gou ML; Dai M; Li XY; Wang XH; Gong CY; Xie Y; Wang K; Zhao X; Qian ZY; Wei YQ
    J Mater Sci Mater Med; 2008 Jul; 19(7):2605-8. PubMed ID: 18197366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy.
    Alam F; Al-Hilal TA; Chung SW; Park J; Mahmud F; Seo D; Kim HS; Lee DS; Byun Y
    J Control Release; 2015 Jan; 197():180-9. PubMed ID: 25445701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.